Boosting capabilities through collaboration
CDMO, Micro-Sphere partners with German machine manufacturer Harro Höfliger for the latest step in its 21 million CHF (€19 million) investment into its facility in Switzerland.
Micro-Sphere, a CDMO specialising in the spray drying of APIs and HPAPIs, noticed a growing interest in using spray drying as a technology for particle engineering in the field of respiratory dry powders. Listening to respected and long-standing clients and keeping abreast of technological advances in the market, the CDMO decided to increase its capabilities, adding new technology to satisfy clients' new needs.
After consulting a number of experts and suppliers, and considering various options, Micro-Sphere concluded their next logical step was to source a technical partner to supply the best available technology to fill spray-dried powder in capsules ‒ the Harro Hofliger Modu-C MS unit.
This capsule filling machine boosts Micro-Sphere’s capsule filling production. A notional production of 72,000 capsules per hour and a 100% net weight check control, grant the correct dose when filling capsules for dry powder inhalers.
Micro-Sphere was satisfied that Harro Höfliger offered the best technology to handle cohesive spray-dried powders for respiratory applications and would be the right partner for the job.
Spray dried powders are sensitive and versatile in terms of physical characteristics and handling needs. The Modu-C Drum dosing technology has the capability to allow for careful powder feeding and precise metering without causing negative impact on final product performance (powder dispersion, stability, etc.) and is therefore the perfect solution for Micro-Sphere's needs.
Adding this capacity has given Micro-Sphere a powerful tool to cover client needs from clinical through to commercial launch.
Micro-Sphere founder and president of the Board, Dr Michele Müller, said: “Low-dose capsule filling is becoming increasingly popular across the market and at present we are the only CDMO in Europe offering this level of capability.
“Harro Höfliger’s powder expertise and technological competence is particularly evident in the Modu-C MS. This investment is an important next step in our expansion plans, allowing us to meet demand for greater capacity and speed up project delivery for our customers.”
Based in Allmersbach, Germany, Harro Höfliger develops and manufactures production and packaging systems and is a valued development partner for many pharmaceutical and medical technology companies.
Marco Laackmann, business unit leader, inhalation at Harro Höfliger added: “The capacitive fill quantity control of the Modu-C MS offers excellent process reliability and is a great choice for Micro-Sphere in line with its continued expansion. We’re delighted to be a part of their exciting future.”
Having been through the process of increasing capsule-filling capabilities, what has Micro-Sphere learnt and what advice can they offer companies in a similar situation?
First, the CDMO would encourage companies to consider collaborative working. "Besides the purchase of a piece of equipment, both companies are technology-driven and service orientated and this has created a positive, winning relationship for both the companies involved and our clients that can have their dry powder inhalers capsules quickly and properly filled under GMP."
It doesn't end with the delivery of the machinery either. Harro Höfliger offers continuous and competent postsale support, and as a result Micro-Sphere is learning how to get the best from the Modu-C-MS unit. Thanks to its clients and Micro-Sphere's spray drying expertise, Harro Höfliger is also learning more about challenges posed by cohesive spray-dried powders.
Micro-Sphere and Harro Höfliger teams are already working together side by side at Micro-Sphere's site to deliver more success stories.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance